Mumbai, July 26, 2017: Zydus Cadila has received the tentative approval from the US Food and Drug Administration (USFDA) to market Sitagliptin and Met for min Hydro chloride Tablets in the strengths of 50 mg/500 mg and 50 mg/1000 mg. This is a fixed dose combination of two anti-diabetic drugs indicated for Type H diabetes mellitus and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
United News Of India
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…